Abstract
Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have